Davorin Radosavljević

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lowell L. Hart, Renata Ferrarotto, Zoran Andrić et al. · Advances in Therapy · 2020 · 121 citations · Full text

CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)

Andrea Ardizzoni, Marcello Tiseo, Luca Boni et al. · Journal of Clinical Oncology · 2006 · 62 citations

Carboplatin-based Chemotherapy, Clinical Endpoint, First-line Treatment +16

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Thomas Brodowicz, Tudor–Eliade Ciuleanu, Davorin Radosavljević et al. · Annals of Oncology · 2013 · 57 citations

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

S. Jelić, Labuda Mitrović, Davorin Radosavljević et al. · Lung Cancer · 2001 · 43 citations

Mitomycin C, Medicine, Pathology +9

Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients

Neda Nikolić, Davorin Radosavljević, Dušica Gavrilović et al. · Medicina · 2021 · 28 citations · Full text